SLC16A1 and neoplasm: Similarly, the blockade of lactate transporter MCT1 by AZD3965 combined to rituximab leads to tumor regression in a BL mouse xenograft [432] as well as in patients with DLBCL (phase I NCT01791595, completed in 2020) [373].